Biological Characteristics and Medical Treatment of Breast Cancer in Young Women—A Featured Population: Results from the NORA Study by Pronzato, P. et al.
SAGE-Hindawi Access to Research
International Journal of Breast Cancer
Volume 2011, Article ID 534256, 6 pages
doi:10.4061/2011/534256
Research Article
Biological Characteristics and Medical Treatmentof
Breast Cancer in Young Women—AFeatured Population:
Results from the NORA Study
P. Pronzato,1 G.Mustacchi,2 A.DeMatteis,3 F.DiCostanzo,4 E.Rulli,5
I. Floriani,5 andM .E.Caz z aniga 6
1Oncologia Medica, IST, Genova 16010, Italy
2Medical Oncology Department, University of Trieste, Trieste 34010, Italy
3Medical Oncology C, National Cancer Institute, G. Pascale Foundation, Napoli 80010, Italy
4Medical Oncology, Careggi University Hospital, Firenze 50012, Italy
5Oncology Department, Mario Negri Institute for Pharmacological Research, Milano 20100, Italy
6Medical Oncology, San Gerardo Hospital, Az Osp San Gerardo, Via Pergolesi 33, 20052 Monza, Italy
Correspondence should be addressed to M. E. Cazzaniga, oncologia@tin.it
Received 24 May 2010; Accepted 16 August 2010
Academic Editor: Lucia Del Mastro
Copyright © 2011 P. Pronzato et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. The present paper described the biological characteristics and clinical behavior of young women in the cohort NORA
study Patients and Methods. From 2000–2002, patients (N>3500) were enrolled at 77 Italian hospitals. Women aged ≤50 years
(N = 1013) were stratiﬁed into age groups (≤35, 36–40, 41–45, and 46–50 years). The relationship between age and patient
characteristics, cancer presentation, and treatment was analyzed. Results. Younger women more frequently had tumors with
ER/PgR-negative(χ2 = 7.07;P = .008),HER2ampliﬁcation(χ2 = 5.76;P = .01),andhigh(≥10%)Ki67labellingindex(χ2 = 9.53;
P = .002). Positive nodal status, large tumors, and elevated Ki67 all associated with the choice for chemotherapy followed by
endocrine therapy in hormone receptor-positive patients (P<. 0001). At univariate analysis, ER-ve status, chemotherapy and age
resulted as the only statistically signiﬁcant variables (HR = 2.02, P = .004, and >40 versus ≤40, P<. 0001, resp.). At multivariate
analysis,afteradjustmentforsigniﬁcantclinicalandpathologicalfactors,ageremainsasigniﬁcantprognosticvariable(HR = 0.93,
P = .0021).Conclusion.Thiscohortstudysuggeststhatagepers` eisanimportantprognosticfactor.Therestrictedroleofearlydiag-
nosis and the aggressive behavior of cancer in this population make necessary the application of targeted medical strategies crucial.
1.Introduction
The incidence of breast cancer increases with age but
is not infrequent in women younger than age 40 years;
approximately 2% of women are younger than 35 years
when breast cancer is diagnosed [1]. Breast cancer has been
reported to be more aggressive and to be associated with a
more unfavorable prognosis in younger patients. Whereas
management problems in older patients tend to be related
to health and social aspects of the aging women, in young
people, other factors, such as familial and reproductive
problems, have to be considered. Trials of premenopausal
or young breast cancer patients have been conducted or are
ongoing, but data from clinical practice are lacking.
The principal aim of the NORA (National Oncological
Research observatory on Adjuvant therapy in breast cancer)
study was to describe treatment strategies and reasons for
their selection in a population of breast cancer patients
radically treated after surgery. This paper presents data
concerning the biological characteristics of breast cancer and
adjuvant treatment strategies in women ≤50 years, stratiﬁed
according to age group.
2. Patients andMethods
The NORA survey was a multicenter, longitudinal, observa-
tional cohort study involving oncology centers at both aca-
demic and nonacademic institutions, which were distributed2 International Journal of Breast Cancer
throughout Italy. Each center was required to register data
on the ﬁrst 10 consecutive patients treated in the years
2000, 2001, and 2002 (retrospective cohort) and on the
ﬁrst 20 consecutive patients who reached the oncology unit
in 2003 (prospective cohort), for a total of 50 patients
per center. These criteria were selected with the aim of
maximizing enrollment while shortening the time needed
to obtain an adequate followup period. Inclusion criteria
included:ﬁrstdiagnosisofinvasivebreastcancerandabsence
of metastatic disease. Women aﬀected by in situ carcinoma
alone or who had undergone surgery with palliative intent
(macroscopic residual disease) were considered ineligible.
Concomitant participation in a clinical study did not qualify
as an exclusion criterion as long as the proportion of these
patients remained below 20% and 40% in the retrospective
and prospective cohorts, respectively. Patients enrolled in a
clinical trial who exceeded these rates were not considered
for the analysis, but only registered. Data on demographic
characteristics, familial and pathological history, diagnostic
methods, surgery, pathological features, and adjuvant treat-
ments were collected. In order to collect data on changes in
adjuvant treatment, toxicity, and cancer-related events, all
patients were followed up every 6 months for a minimum
o f4t oam a x i m u mo f8y e a r s .
The study complied with the requirements of Italian law
regarding observational studies. The nature and purposes of
the survey were explained in detail to all potential partici-
pants, and their consent to data handling according to Italian
privacy regulations was obtained. Assuming involvement of
approximately 70 centers with a minimum recruitment of 50
patients, investigators planned to enroll approximately 3500
women. This number allows an estimate of the distribution
of adjuvant strategies with a 95% conﬁdence interval (CI)
range of no more than 3%.
This paper presents data on the biological characteristics
and medical treatment of women ≤50 years old. To better
study the inﬂuence of age on patterns of care and the distri-
bution of selected factors related to patient characteristics,
we identiﬁed four groups: ≤35, 36–40, 41–45, and 46–50
years.Thecharacteristicsofselectedfactorsacrossagegroups
were described by relative and absolute frequencies. We were
not able to detail menopausal status, mainly because data in
the retrospective cohort were lacking or largely incomplete.
Analyses were performed using the Mantel-Haenszel test
for trend and the chi-square test for heterogeneity. Cox’s
model was applied for univariate analysis. Unless otherwise
speciﬁed, all tests were within one degree of freedom.
3. Results
A total of 3532 breast cancer patients were enrolled by 71
Italian centers. Seventeen patients (0.5%) were subsequently
excluded because of synchronous tumors, leaving 3515
evaluable patients. Academic institutions comprised 21.2%
of the centers; 42.3% were located in northern Italy, 28.2%
in central Italy, and 29.6% in southern Italy and the
islands. Therefore, the institutions were well distributed and
representative of the country.
Table 1: Age distribution at the time of study entry.
Age (years) N %
≤35 78 7.7
35–40 163 16.1
41–45 308 30.4
46–50 463 45.8
Median age: 44.4 (minimum-maximum: 24–50).
Baseline characteristics and pathological features of the
entire patient population have been reported previously [2].
Brieﬂy, the median age of the patients in the whole popu-
lation was 58 years (range 25–92); almost all of them had a
goodECOGPS(0-1:98.2%)andwerepostmenopausalwhen
breast cancer was diagnosed (72.3%). Approximately one-
third of the patients had a positive history of cardiovascular
(24.1%) or gynaecological (13.2%) comorbidities. At the
time of study entry, 1013 (28.8%) patients were ≤50 years
(Table 1), and most of them were not menopausal (79.8%).
The median age was 44.4 years (minimum-maximum value:
24–50). Comorbidities are infrequent in the majority of the
patients <35 years (18.2%) and tend to be more present with
increasing age (χ2 = 16.87; P<. 0001), particularly skeletal
diseases.
Breast cancer was detected by self-examination in the
majority of patients ≤35 years (80%) and by periodic
screening programs in those 40–45 years (23.5%) and 45–50
years (23.8%), which is similar to that observed in the whole
population (Table 2).
Conservative surgery was performed in 66.4% of the
cases, without any signiﬁcant diﬀerence across age groups
(χ2 = 1.35; P = .24). In the ≤35 age group, mastectomy was
performed in 34.6% of the cases, despite the fact that small
tumors(<2cm)werefoundin57.7%ofthepatients.Sentinel
node technique was used together with conservative surgery
in14.1%ofthecases,withoutanydiﬀerenceaccordingtoage
group (χ2 = 0.02; P = .87).
Histologic characteristics were similar among all sub-
groups, except for the lobular subtype, which tended to
be more frequent among women older than 35 years
and was rare in women ≤35 years (10.5% versus 2.6%,
resp.).
3.1. pTN Stage and Biological Characteristics. T stage and
nodal involvement (TN) as well as the chief biological
characteristics are reported in Table 3. The distribution of
TNstagedidnotdiﬀeraccordingtoagegroup(χ2 =2.18;P =
.13); on the contrary, hormone receptor status, human epi-
dermal growth factor receptor 2 (HER2) ampliﬁcation, and
elevated Ki67 labelling index showed statistically signiﬁcant
correlations with age (Tables 4 and 5), being more frequently
present in the group younger than 35 years. Thus, the
t u m o u r so fy o u n g e rw o m e nw e r em o r ef r e q u e n t l ye s t r o g e n
receptor (ER)/progesterone receptor (PgR)-negative (χ2 =
7.07; P = .008), HER2 ampliﬁed (χ2 = 5.76; P = .01),
and with high (≥10%) Ki67 labelling index (χ2 = 9.53;
P = .002).International Journal of Breast Cancer 3
Table 2: Diagnosis of breast cancer—n (%).
≤35 (%) 36–40 (%) 41–45 (%) 46–50(%) Total (%)
Self-breast examination 56 (80.0) 92 (66.7) 151 (56.3) 194 (49.6) 493 (56.9)
Periodical screening 3 (4.3) 9 (66.7) 63 (23.5) 93 (23.8) 168 (19.4)
Occasional ﬁnding 11 (15.7) 37 (26.8) 53 (19.8) 101 (25.8) 202 (23.3)
Other 4
Missing 145
χ2 = 45.53; P<. 001.
Table 3: TN stage according to age groups—n (%).
≤35 (%) 36–40 (%) 41–45 (%) 46–50(%) Total (%)
PT
∗
1 45 (57.7) 88 (54.7) 194 (63.0) 294 (63.8) 621 (61.6)
PT2 30 (38.5) 63 (39.1) 103 (33.4) 147 (31.9) 343 (34.0)
PT3 2 (2.6) 10 (6.2) 5 (1.6) 12 (2.6) 29 (2.9)
PT4 1 (1.3) 0 (0.0) 6 (2.0) 8 (7.0) 15 (1.5)
PN
∗∗
0 44 (57.9) 84 (52.5) 154 (51.9) 269 (59.7) 551 (54.4)
PN1–3 21 (27.6) 38 (23.8) 89 (29.1) 126 (27.9) 274 (27.8)
PN4–10 5 (6.6) 25 (15.6) 35 (11.8) 35 (7.8) 100 (10.2)
PN>10 6 (7.9) 13 (8.1) 19 (6.4) 21 (4.7) 59 (6.0)
Missing 28
∗χ2 = 2.18; P = .13.
∗∗χ2 = 3.06; P = .08.
3.2. Adjuvant Medical Treatment. The choice of adjuvant
medical treatment also correlated with age. Endocrine
therapy alone was more frequently administered to women
older than 35 years (≤35: 0%; 36–40: 7.4%; 41–45: 14.9%;
45–50: 20.1%) whereas younger women were more likely to
receive chemotherapy alone or chemotherapy followed by
endocrine therapy (χ2 = 35.43; P<. 0001). If we analyse
the choice of adjuvant therapy according to the hormone
status (Table 6), we observe that almost all patients who
were ER+/PgR+ received endocrine therapy alone or chemo-
followed by endocrine therapy, independently of age, even if
older patients were most likely to be treated with a treatment
containing hormones, in comparison to younger ones. This
ﬁnding is consistent with the more frequent presence of
hormone receptors in older women (χ2 = 699.89; P<. 0001).
No diﬀerences were observed in the type of adjuvant
chemotherapy (χ2 = 12.09; P = .2). Anthracycline-based
chemotherapy was the preferred choice in the whole group
( 6 5 . 2 % )a sw e l la si na l ls u b g r o u p so fp a t i e n t s( Table 7).
Endocrine therapy alone was administered in 151
patients. Eighty-one patients received tamoxifen and 70
a luteinizing hormone-releasing hormone (LHRH) ana-
logue with or without tamoxifen. Of 636 patients who
received chemotherapy followed by endocrine therapy, an
anthracycline-based regimen was chosen in 352 (55.8%);
cyclophosphamide, methotrexate, and ﬂuorouracil in 233
(37%), and a taxane-based therapy in 39 (6.2%).
The choice between endocrine therapy and chemother-
apy was mainly based on the patient’s hormone receptor
status. Endocrine therapy was widely used in hormone
receptor-positivepatients,whilechemotherapywaspreferred
in patients who were hormone receptor-negative (χ2 =
699.89; P<. 0001).
In the hormone receptor-positive population, the pref-
erence for chemotherapy followed by endocrine therapy was
strongly inﬂuenced by nodal status (N+ versus N−: 69.6%
versus 97.9%; χ2 = 102.20; P<. 0001), T stage (T1 versus
T>1: 73.8% versus 95%; χ2 = 56.15; P<. 0001), and elevated
Ki67 (≤10% versus >10%; χ2 = 15.43; P<. 0001). The
lack of expression of PgR did not seem to inﬂuence the
choice between endocrine therapy alone or chemotherapy
followed by endocrine therapy (P = .6), but no conclusion
could be drawn regarding the inﬂuence of HER2 status
because of the high percentage of missing values. The
menopausal status did not have any relevance on the choice
between chemotherapy or endocrine therapy (χ2 = 0.68;
P = .71).
There was a statistically signiﬁcant diﬀerence among age
groups in terms of DFS (Figure 1(a)). The worse prognosis
was observed in those aged 35–40 (χ2 = 27.69; P<
.0001). There were no signiﬁcant diﬀerences between age
groups in terms of overall survival (OS); however, OS was
statistically better in younger patients compared with the
total population studied (Figure 1(b)).
At univariate analysis, ER-ve status (HR = 2.02, P =
.004), choice for chemotherapy (HR = 4.45, P = .019),
and age (<40 versus ≤40, HR = 0.34, P<. 0001) were
independent variables all associated with worse DFS.
At multivariate analysis, when adjusted for the clinical
and biological factors signiﬁcant at univariate analysis,
age remains a statistically signiﬁcant independent variable
(HR = 0.39, P<. 0001) for worse DFS.4 International Journal of Breast Cancer
Table 4: Human epidermal growth factor receptor 2 (HER2)-neu and labelling index according to age. Younger age correlates with HER2-
neu positive status and high Ki67.
HER2 status
≤35 (%) 36–40 (%) 41–45 (%) 46–50(%) Total (%)
HER2 0 14 (35.9) 31 (34.4) 52 (36.9) 100 (44.6) 197 (39.9)
HER2 1+ 6 (15.4) 18 (20.0) 28 (19.9) 42 (18.8) 94 (19.0)
HER2 2+ 6 (15.4) 16 (17.8) 28 (19.9) 45 (20.1) 95 (19.2)
HER2 3+ 13 (33.3) 25 (27.8) 33 (23.4) 37 (16.5) 108 (21.9)
Missing 518
Labelling index—Ki 67
Ki67 ≤10% 5 (8.1) 28 (23.1) 56 (24.2) 99 (27.3) 188 (24.2)
Ki67 >10%∗ 57 (91.9) 93 (76.9) 175 (75.8) 264 (72.7) 589 (75.8)
Missing 235
∗χ2 = 9.53; P = .002.
Table 5: Hormone receptor status stratiﬁed by age group. Younger
age more frequently correlates with lack of hormone receptors.
HR status
PgR status
PgR+ PgR− Total
N % N % N %
≤35 years
ER+ 43 58.1 6 8.1 49 66.2
ER− 6 8.1 19 25.7 25 33.8
Total 49 66.2 25 33.8 74 100.0
36–40 years
ER+ 106 66.3 18 11.3 124 77.5
ER− 5 3.1 31 19.4 36 22.5
Total 111 69.4 49 30.6 160 100.0
41–45 years
ER+ 199 66.1 26 8.6 225 74.8
ER− 15 5.0 61 20.3 76 25.2
Total 214 71.1 87 28.9 301 100.0
46–50 years
ER+ 328 72.6 34 7.5 362 80.1
ER− 19 4.2 71 15.7 90 19.9
Total 347 76.8 105 23.2 452 100.0
χ2 = 7.07; P = .0078.
ER: estrogen receptor. HR: hormone receptor. PgR: progesterone receptor.
4. Discussion
The population analyzed in this paper consisted of 1014
women ≤50 years of age. As expected, the majority of
the patients did not have the comorbidities observed in
older women [3] that can limit the choice of treatment. Yet
even among women aged 41–50, the risk of cardiovascular,
skeletal, and gynecological disease may be important enough
to have an impact on treatment selection.
At the time patients entered the cohort study, evidence
did not support a screening mammogram in these women.
Nevertheless, 34.3% of the patients in this age group had
their breast cancer diagnosed by a periodic screening test.
This could be interpreted as a sporadic ﬁnding. Debate
Table 6: Adjuvant treatment according to hormone receptor status
andage.EndocrinetherapyismorefrequentlyadministeredinHR+
patients, independently of age (χ2 = 699.89; 6df; P<. 0001).
HT CHT CHT-HT
N % N % N %
ER+/PgR+
≤35 0 0 3 7.1 39 92.9
36–40 10 9.5 8 7.6 87 82.9
41–45 40 20.4 6 3.1 150 76.5
46–50 78 23.9 5 1.5 243 74.5
ER+/PgR−
≤35 0 0 0 0 6 100.0
36–40 1 5.6 1 5.6 16 88.9
41–45 3 12.0 2 8.0 20 80.0
46–50 10 29.4 2 5.9 22 64.7
ER−/PgR+
≤35 0 0 2 33.3 4 66.7
36–40 0 0 0 0 5 100.0
41–45 0 0 5 33.3 10 66.7
46–50 3 15.8 5 26.3 11 57.9
ER−/PgR−
≤35 0 0 17 89.5 2 10.5
36–40 0 0 29 93.5 2 6.5
41–45 1 1.7 55 91.7 4 6.7
46–50 0 0 65 95.6 3 4.4
continues about the validity of a screening mammography
program for women younger than 45 years. Issues include
the lower sensitivity of mammography in this subset of
patients,thehighrateoffalse-positives,andhealthcarecosts.
However, the high rate of women spontaneously screened in
this study could be the starting point for a more rational and
cost-eﬀective approach in this age group.
These data demonstrate that tumors that occur in very
young (<35 years) women are characterized by a lack of
hormone receptors and a high proliferation rate. Our results
are similar to those described by Colleoni et al. [4]. This
study was a cohort trial; thus no centralized revision of HR
status or Ki67 was planned; concerning the HER2 status, we
must keep in mind that these data were collected starting
from 2000, when the determination was not routinely
applied. With HER2-neu status being determined moreInternational Journal of Breast Cancer 5
Table 7: Type of adjuvant therapy in the young population and in the subgroups stratiﬁed by age.
≤35 (%) 36–40 (%) 41–45 (%) 46–50(%) Total (%)
No therapy 1 (1.3) 1 (0.6) 5 (1.6) 6 (1.3) 13 (1.3)
HT alone 0 12 (7.4) 46 (14.9) 93 (20.1) 151 (14.9)
CHT alone 23 (29.5) 39 (23.9) 70 (22.7) 80 (17.3) 212 (20.9)
CHT followed by HT 54 (69.2) 111 (68.1) 187 (60.7) 284 (61.3) 636 (62.8)
35–40+
40–45+
45–50+
> 50
0.7
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0.8
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Figure 1: (a) Disease-free survival (DFS), and (b) overall survival (OS) according to age group.
often, very young women with breast cancer are more often
found to have tumors that amplify HER2-neu in comparison
with older patients (χ2 = 5.76; P = .01).
In young patients, appropriate therapies may ameliorate
the unfavorable prognostic features associated with age. In
a study by Kroman et al. [5], young patients who did not
receive adjuvant therapy had a worse prognosis than older
patients with the same biological characteristics whereas for
patientswhoreceivedadjuvanttreatment,irrespectiveofage,
a worse prognosis was not evident.
While chemotherapy was administered to almost all
women who were ER/PgR−, and endocrine therapy was
given to patients with tumors that were clearly endocrine-
responsive, the sequence of chemotherapy and endocrine
therapy was chosen for the majority of patients with tumor
expressionofatleastoneofthetworeceptors.Thistreatment
choice in patients with endocrine-sensitive breast cancer has
been vigorously discussed. Some retrospective analyses have
argued that the value of such a treatment sequence is limited
in patients with endocrine-positive disease [6]. However,
the INT 0101 trial [7], which randomized premenopausal
patients to chemotherapy alone, chemotherapy plus LHRH
analogs for 5 years or the same treatment with the addition
of tamoxifen, demonstrated the superiority of the latter arm
over the other two choices.
TheseresultsaresimilartothosedescribedbyReganet al.
[8], who recently analyzed the determinants for choosing
chemotherapy in a population of hormone receptor-positive
premenopausal patients enrolled in three diﬀerent Interna-
tionalBreastCancerStudyGrouptrials.Positivenodalstatus,
higher grade tumors, and large tumors were all factors for
choosing chemotherapy.
In premenopausal women, the eﬀectiveness of chemo-
therapy may also be related to the induction of menopause,
which has an endocrine-like eﬀect. Studies comparing end-
ocrine therapy with chemotherapy have not demonstrated
relevant diﬀerences [9–11]. However, with the development
of second- and third-generation chemotherapy regimens
such as CEF, dose-dense paclitaxel, and dose-dense EC Taxol,
whicharemoreeﬀectivethanstandardBonadonnaCMF,and
AC alone, no ﬁnal conclusions should be drawn from studies
that compare “ﬁrst generation” chemotherapies with ovarian
ablation. In this cohort study, it was quite clear that Italian
oncologistspreferredtheuseofsequentialchemotherapyand
endocrinetherapy.However,inmostcases,thechoicewasfor
a “new” anthracycline-based regimen.6 International Journal of Breast Cancer
5. Conclusions
In young patients with breast cancer, management problems
speciﬁc to this patient population could arise. In this
cohort study, investigators collected data on a large series
of patients aged ≤50 years who were treated in clinical
practice throughout Italy, outside of controlled clinical trials.
The results conﬁrm previous ﬁndings obtained by other
observational trials, in particular, evidence of unfavorable
biological and pathological patterns. The concept of young
age as a negative prognostic factor most likely led oncologists
tochoose moreaggressivetreatments,suchaschemotherapy.
Because of the restricted role of early diagnosis and the
aggressive behaviour of cancer in this patient population,
the application of validated medical strategies is of critical
importance.
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